Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076043 | 0.83 | TDP1 (0.55) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL5115366 | 0.80 | TDP1 (0.57) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL5074228 | 0.79 | TDP1 (0.50) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL34204 | 0.76 | — | — | |
| SCHEMBL8052335 | 0.76 | — | — | |
| SCHEMBL5075526 | 0.74 | CYP3A4 (0.45) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL19514044 | 0.74 | CYP3A4 (0.45) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL11661411 | 0.74 | CYP3A4 (0.45) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL23243497 | 0.74 | TDP1 (0.50) | ESR1ESR2TDP1CYP3A4TSHR | |
| SCHEMBL9217677 | 0.74 | TDP1 (0.50) | ESR1ESR2TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1205494-B1 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymers | SUMITOMO CHEMICAL CO (JP) | 2008-04-09 | — | — | EP | disclosed |
| US-6723807-B2 | CYCLOPENTADIENE METAL COMPLEX WITH NITROGEN AND AN ORGANOALUMINUM, AND AN ALUMINOXANE AND/OR BORON COMPOUND; HIGH ACTIVITY. | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20030158355-A1 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-08-21 | — | — | US | disclosed |
| US-20020091209-A1 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-07-11 | — | — | US | disclosed |
| EP-1205494-A1 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091209-A1 | Catalyst component and catalyst for addition polymerization, and process for producing addition polymer | ZYX, MLX, AP1M1 | ESR1 4071/4885ESR2 3988/4885TDP1 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.